Literature DB >> 24869801

Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.

Antonia Valenzuela1, Lorinda Chung2, Livia Casciola-Rosen3, David Fiorentino2.   

Abstract

IMPORTANCE: Prior studies have estimated that up to 20% of adults with dermatomyositis (DM) have calcinosis, which can lead to significant morbidity. Identification of risk factors may provide a better understanding of the pathogenesis and ultimately therapy for this difficult clinical problem. Risk factors for calcinosis in adults with DM have not been extensively studied.
OBJECTIVES: To determine the prevalence of calcinosis and to identify associated clinical features in a cohort of extensively phenotyped adults with DM. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study of 126 patients diagnosed as having DM from January 1, 2006, through January 1, 2013, was performed. Patients were adults (≥18 years of age) attending the Stanford University Medical Center clinic. MAIN OUTCOMES AND MEASURES: Calcinosis, defined as the presence of calcium deposition in the skin and subcutaneous tissues on physical examination.
RESULTS: Fourteen patients (11.1%) had calcinosis, with the extremities most commonly involved. Patients with vs those without calcinosis had a longer disease duration (median, 6.9 years; range, 2.4-18.1; vs median, 3.9 years; range, 0.2-19.2 years; P = .003) and more fingertip ulcers (50.0% vs 9.3%, P < .001). An association between calcinosis and both interstitial lung disease and anti-MDA-5 autoantibodies was identified, but this association did not persist in multivariate models that adjusted for fingertip ulcers. Fingertip ulcers and disease duration were strongly associated with calcinosis in all multivariate models, independent of the underlying autoantibody present. Autoantibodies to NXP-2 were associated with calcinosis (odds ratio, 15.52; 95% CI, 2.01-119.90), whereas anti-transcriptional intermediary factor 1-γ antibodies were protective (odds ratio, 0.2; 95% CI, 0.01-0.99) in multivariate analyses that adjusted for fingertip ulcers and other covariates. CONCLUSIONS AND RELEVANCE: Calcinosis was a relatively uncommon clinical feature in our cohort of adults with DM. Our data suggest that calcinosis is positively associated with longer disease duration, fingertip ulcers, and NXP-2 autoantibodies and negatively associated with transcriptional intermediary factor 1-γ antibodies. A common vascular mechanism may underlie the development of both calcinosis and fingertip ulcers in patients with DM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24869801      PMCID: PMC4351704          DOI: 10.1001/jamadermatol.2013.10416

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  31 in total

1.  Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity.

Authors:  L Casciola-Rosen; F Andrade; D Ulanet; W B Wong; A Rosen
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

Review 2.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

3.  Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009.

Authors:  Samuel J Balin; David A Wetter; Louise K Andersen; Mark D P Davis
Journal:  Arch Dermatol       Date:  2011-12-19

Review 4.  Soft tissue and subcutaneous calcification in connective tissue diseases.

Authors:  Sumeet Chander; Patrick Gordon
Journal:  Curr Opin Rheumatol       Date:  2012-03       Impact factor: 5.006

5.  Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.

Authors:  Yuki Ichimura; Takashi Matsushita; Yasuhito Hamaguchi; Kenzo Kaji; Minoru Hasegawa; Yoshinori Tanino; Yayoi Inokoshi; Kazuhiro Kawai; Takuro Kanekura; Maria Habuchi; Atsuyuki Igarashi; Ryosuke Sogame; Takashi Hashimoto; Tomohiro Koga; Ayako Nishino; Naoko Ishiguro; Naoki Sugimoto; Rui Aoki; Noriko Ando; Tetsuya Abe; Takashi Kanda; Masataka Kuwana; Kazuhiko Takehara; Manabu Fujimoto
Journal:  Ann Rheum Dis       Date:  2012-01-17       Impact factor: 19.103

Review 6.  Calcifying disorders of the skin.

Authors:  J S Walsh; J A Fairley
Journal:  J Am Acad Dermatol       Date:  1995-11       Impact factor: 11.527

7.  Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset.

Authors:  Helga Sanner; Jan-Tore Gran; Ivar Sjaastad; Berit Flatø
Journal:  Rheumatology (Oxford)       Date:  2009-09-23       Impact factor: 7.580

8.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  L G Rider; B M Feldman; M D Perez; R M Rennebohm; C B Lindsley; L S Zemel; C A Wallace; S H Ballinger; S L Bowyer; A M Reed; M H Passo; I M Katona; F W Miller; P A Lachenbruch
Journal:  Arthritis Rheum       Date:  1997-11

Review 9.  Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Authors:  Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

10.  Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis.

Authors:  Angela Ceribelli; Micaela Fredi; Mara Taraborelli; Ilaria Cavazzana; Franco Franceschini; Marzia Quinzanini; Angela Tincani; Steven J Ross; Jason Y F Chan; Brad A Pauley; Edward K L Chan; Minoru Satoh
Journal:  Arthritis Res Ther       Date:  2012-04-30       Impact factor: 5.156

View more
  28 in total

1.  Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.

Authors:  Jemima Albayda; Iago Pinal-Fernandez; Wilson Huang; Cassie Parks; Julie Paik; Livia Casciola-Rosen; Sonye K Danoff; Cheilonda Johnson; Lisa Christopher-Stine; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11       Impact factor: 4.794

Review 2.  [Dermatomyositis-specific antibodies].

Authors:  L Bodoki; M Nagy-Vincze; Z Griger; K Dankó
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

3.  Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients.

Authors:  Anna Rogers; Lorinda Chung; Shufeng Li; Livia Casciola-Rosen; David F Fiorentino
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11-02       Impact factor: 4.794

Review 4.  Autoimmune Myopathies.

Authors:  Andrew L Mammen
Journal:  Continuum (Minneap Minn)       Date:  2016-12

Review 5.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 6.  Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

Review 7.  Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.

Authors:  Liubing Li; Chenxi Liu; Linlin Cheng; Songxin Yan; Haizhen Chen; Yongzhe Li
Journal:  Clin Rheumatol       Date:  2020-07-17       Impact factor: 2.980

Review 8.  A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.

Authors:  Minoru Satoh; Shin Tanaka; Angela Ceribelli; S John Calise; Edward K L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

9.  Association of Dermatomyositis Sine Dermatitis With Anti-Nuclear Matrix Protein 2 Autoantibodies.

Authors:  Michio Inoue; Jantima Tanboon; Shinya Hirakawa; Hirofumi Komaki; Takeshi Fukushima; Hiroyuki Awano; Takashi Tajima; Kenji Yamazaki; Ryutaro Hayashi; Tatsuo Mori; Kazumoto Shibuya; Takahiko Yamanoi; Hajime Yoshimura; Tomohiro Ogawa; Atsushi Katayama; Fuminobu Sugai; Yoichi Nakayama; Satoko Yamaguchi; Shinichiro Hayashi; Satoru Noguchi; Hisateru Tachimori; Naoko Okiyama; Manabu Fujimoto; Ichizo Nishino
Journal:  JAMA Neurol       Date:  2020-07-01       Impact factor: 18.302

Review 10.  Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay.

Authors:  Li Wang; Li Huang; Yang Yang; Huan Chen; Yanjuan Liu; Ke Liu; Meidong Liu; Yizhi Xiao; Hui Luo; Xiaoxia Zuo; Yisha Li; Xianzhong Xiao; Huali Zhang
Journal:  Clin Rheumatol       Date:  2018-07-23       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.